Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.47 |
| ▸ | RAB7A | P51149 | 3/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21247104 | 0.89 | MEN1 (0.54) | MEN1KMT2ANOD1MAPTLMNA | |
| SCHEMBL21261092 | 0.84 | GLO1 (0.72) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL21260924 | 0.82 | MEN1 (0.74) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL21247290 | 0.80 | GLO1 (0.53) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL19140543 | 0.80 | RAB7A (0.51) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL21260681 | 0.80 | MAPT (0.64) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL19321421 | 0.79 | RAB7A (0.50) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL19321392 | 0.79 | RAB7A (0.50) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL19326445 | 0.78 | RAB7A (0.49) | GLO1MEN1KMT2ANOD1MAPT | |
| SCHEMBL19326457 | 0.78 | RAB7A (0.49) | GLO1MEN1KMT2ANOD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492347-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2022-11-08 | — | — | US | disclosed |
| EP-3749659-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | GLO1 616/4885MEN1 3538/4885KMT2A 3454/4885 |
| US-11492347-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | GLO1 616/4885MEN1 3538/4885KMT2A 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.